Briacell Therapeutics Corp reports results for the quarter ended January 31 - Earnings Summary

• Briacell Therapeutics Corp BCT.TO reported a quarterly adjusted loss of $2.33​​ per share for the quarter ended January 31, higher than the same quarter last year, when the company reported EPS of $-10.65. The lone analyst forecast for the quarter was for a loss of $1.94 per share.

• Reported revenue was zero​; analysts expected zero.

• Briacell Therapeutics Corp's reported EPS for the quarter was a loss of $2.33​.

• The company reported a quarterly loss of $6.29 million.

• Briacell Therapeutics Corp shares had fallen by 54.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 52.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Briacell Therapeutics Corp is $225.00

This summary was machine generated from LSEG data March 17 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)